Cited by 384HIV-related health complications and treatmentsLipoproteins and Cardiovascular HealthHIV/AIDS Research and Interventions

The DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.

Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study

Open access

Friis-Møller, Nina, Thiébaut, Rodolphe, Reiss, Peter, Weber, Rainer, D'Arminio Monforte, Antonella, De Wit, Stephane, El-Sadr, Wafaa, Fontas, Eric, Worm, Signe, Kirk, Ole, Phillips, Andrew, Sabin, Caroline A., Lundgren, Jens D., Law, Matthew G., DAD study group·2010·European Journal of Cardiovascular Prevention & Rehabilitation

DOI 10.1097/hjr.0b013e328336a150

Open this paper in CoChat — free account

Abstract

AIMS: HIV-infected patients receiving combination antiretroviral therapy may experience metabolic complications, potentially increasing their risk of cardiovascular diseases (CVDs). Furthermore, exposures to some antiretroviral drugs seem to be independently associated with increased CVD risk. We aimed to develop cardiovascular risk-assessment models tailored to HIV-infected patients. METHODS AND RESULTS: Prospective multinational cohort study. The data set included 22,625 HIV-infected patients from 20 countries in Europe and Australia who were free of CVD at entry into the Data collection on Adverse Effects of Anti-HIV Drugs Study. Using cross-validation methods, separate models were developed to predict the risk of myocardial infarction, coronary heart disease, and a composite CVD endpoint. Model performance was compared with the Framingham score. The models included age, sex, systolic blood pressure, smoking status, family history of CVD, diabetes, total cholesterol, HDL cholesterol and indinavir, lopinavir/r and abacavir exposure. The models performed well with area under the receiver operator curve statistics of 0.783 (range 0.642-0.820) for myocardial infarction, 0.776 (0.670-0.818) for coronary heart disease and 0.769 (0.695-0.824) for CVD. The models estimated more accurately the outcomes in the subgroups than the Framingham score. CONCLUSION: Risk equations developed from a population of HIV-infected patients, incorporating routinely collected cardiovascular risk parameters and exposure to individual antiretroviral therapy drugs, might be more useful in estimating CVD risks in HIV-infected persons than conventional risk prediction models.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/hjr.0b013e328336a150

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study
Yusuf, S., Hawken, S., Ôunpuu, S., Dans, T., Avezum, A., Lanas, F., McQueen, M., Budaj, A., Pais, P., Varigos, J., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17018-9 · Cited by 12,026
Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies
(2002) · The Lancet · doi:10.1016/s0140-6736(02)11911-8 · Cited by 10,266
Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths
(2007) · The Lancet · doi:10.1016/s0140-6736(07)61778-4 · Cited by 2,331
Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents.
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
CD4+ Count–Guided Interruption of Antiretroviral Treatment
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062360 · Cited by 2,250
Cardiovascular disease risk profiles
Anderson, K. M., Odell, P. M., Wilson, P. W. F., & Kannel, W. B. (1991) · American Heart Journal · doi:10.1016/0002-8703(91)90861-b · Cited by 2,163
Validation of the Framingham Coronary Heart Disease Prediction Scores: Results of a Multiple Ethnic Groups Investigation
D'Agostino, R. B., Grundy, S., Sullivan, L. M., Wilson, P., & for the CHD Risk Prediction Group (2001) · JAMA · doi:10.1001/jama.286.2.180 · Cited by 2,108
Combination Antiretroviral Therapy and the Risk of Myocardial Infarction
El-Sadr, W. M., & The Data Collection On Adverse Events Of Anti-HIV Drugs (DAD) Study Group (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030218 · Cited by 1,677
Self-citation
Increased acute myocardial infarction rates and cardiovascular risk factors among patients with human immunodeficiency virus disease
Triant, V. A., Lee, H., Hadigan, C., & Grinspoon, S. K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2190 · Cited by 1,613
Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa062744 · Cited by 1,521

Show all 43 references

Research works printed but not linked: 5

Lang S, 2009, Impact of specific NRTI and PI exposure on the risk of myocardial infarction: a case-control study nested within FHDH ANRS CO4
Benard A, 2006, Int J Tuberc Lung Dis, 10, 378
Patel N, 2006, Clin Occup Environ Med, 5, 193
Barrett-Connor EL, 1991, JAMA, 265, 627, 10.1001/jama.1991.03460050081025 · DOI
Friis-Moller N, 2007, Predicting the Risk of Coronary Heart Disease in HIV-infected Patients: The D:A:D Risk Equation

Sorted by citations

Items 101–200 of 384

Silent Ischemic Heart Disease and Pericardial Fat Volume in HIV-Infected Patients: A Case-Control Myocardial Perfusion Scintigraphy Study
Kristoffersen, U. S., Lebech, A., Wiinberg, N., Petersen, C. L., Hasbak, P., Gutte, H., Jensen, G. B., Hag, A. M. F., Ripa, R. S., & Kjær, A. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072066 · Cited by 37
Age-specific associations between HIV infection and carotid artery intima-media thickness in China: a cross-sectional evaluation of baseline data from the CHART cohort
Lin, H., Ding, Y., Ning, C., Qiao, X., Chen, X., Chen, X., Shen, W., Liu, X., Hong, Y., & He, N. (2019) · The Lancet HIV · doi:10.1016/s2352-3018(19)30263-2 · Cited by 37
Diagnosis of subclinical atherosclerosis in HIV-infected patients: higher accuracy of the D:A:D risk equation over Framingham and SCORE algorithms
Villar, S. S., Estrada, V., Gómez‐Garré, D., Ávila, M., Fuentes, M. E., San, R. J., Soriano, V., Sánchez-Parra, C., Sainz, T., & Fernández‐Cruz, A. (2012) · European Journal of Preventive Cardiology · doi:10.1177/2047487312452964 · Cited by 37
Soluble biomarkers and morbidity and mortality among people infected with HIV: summary of published reports from 1997 to 2010
Neaton, J. D., Neuhaus, J., & Emery, S. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833ed75d · Cited by 36
A pilot study of brisk walking in sedentary combination antiretroviral treatment (cART)- treated patients: benefit on soluble and cell inflammatory markers
Bonato, M., Galli, L., Passeri, L., Longo, V., Pavei, G., Bossolasco, S., Bertocchi, C., Cernuschi, M., Balconi, G., Merati, G., et al. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-016-2095-9 · Cited by 38
An Inducible Cell-Cell Fusion System with Integrated Ability to Measure the Efficiency and Specificity of HIV-1 Entry Inhibitors
Herschhorn, A., Finzi, A., Jones, D. M., Courter, J. R., Sugawara, A., Smith, A. B., & Sodroski, J. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026731 · Cited by 37
Predictive Performance of Cardiovascular Disease Risk Prediction Algorithms in People Living With HIV
van Zoest, R. A., Law, M. G., Sabin, C. A., Vaartjes, I. C. H., van der Valk, M., Arends, J. E., Reiss, P., Wit, F. W. N. M., & Cohort, O. B. O. T. A. N. O. H. (2019) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000002069 · Cited by 35
Self-citation
Cardiovascular disease in HIV patients: recent advances in predicting and managing risk
McGettrick, P., Mallon, P. W. G., & Sabin, C. A. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2020.1757430 · Cited by 38
Self-citation
The association between alcohol use and cardiovascular disease among people living with HIV: a systematic review
Kelso, N. E., Sheps, D. S., & Cook, R. L. (2015) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2015.1058812 · Cited by 34
Cardiovascular Disease and Therapeutic Drug-Related Cardiovascular Consequences in HIV-Infected Patients
Fisher, S. D., Kanda, B., Miller, T. L., & Lipshultz, S. E. (2011) · American Journal of Cardiovascular Drugs · doi:10.2165/11594590-000000000-00000 · Cited by 34
Malnutrition in hospitalized people living with HIV/AIDS: evidence from a cross-sectional study from Chengdu, China.
Hu, W., Jiang, H., Chen, W., He, S., Deng, B., Wang, W.-Y., Wang, Y., Lu, C. D., Klassen, K., & Zeng, J. (2011) · PubMed · Cited by 34
Management issues in HIV-associated neurocognitive disorders
Cysique, L. A., Bain, Lanĕ, & Brew, B. J. (2012) · Neurobehavioral HIV Medicine · doi:10.2147/nbhiv.s30466 · Cited by 34
A dedicated clinic for HIV-positive individuals over 50 years of age: a multidisciplinary experience
Waters, L. J., Patterson, B., Scourfield, A., Hughes, A., de Silva, S., Gazzard, B., Barton, S. E., Asboe, D., Pozniak, A., & Boffito, M. (2012) · International Journal of STD & AIDS · doi:10.1258/ijsa.2012.011412 · Cited by 33
Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease
Guo, F., Hsieh, E., Lv, W., Han, Y., Xie, J., Li, Y., Song, X., & Li, T. (2017) · BMC Infectious Diseases · doi:10.1186/s12879-017-2358-0 · Cited by 33
HIV Care Among Elderly Population: Systematic Review and Meta-Analysis
Bhatta, M., Nandi, S., Dutta, N., Dutta, S., & Saha, M. K. (2020) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2019.0098 · Cited by 33
Plasma Lipidomic Profiling of Treated HIV-Positive Individuals and the Implications for Cardiovascular Risk Prediction
Wong, G., Trevillyan, J. M., Fatou, B., Cinel, M. A., Weir, J. M., Hoy, J., & Meikle, P. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0094810 · Cited by 33
The metabolic syndrome in HIV
Worm, S. W., & Lundgren, J. D. (2011) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2010.10.018 · Cited by 33
Self-citation
Association Between Depressive Symptom Patterns and Clinical Profiles Among Persons Living with HIV
Chichetto, N. E., Okafor, C. N., Cook, R. L., Abraham, A. G., Bolan, R., & Plankey, M. W. (2017) · AIDS and Behavior · doi:10.1007/s10461-017-1822-6 · Cited by 33
Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment ( START ) trial
Soliman, E. Z., Sharma, S., Arastéh, K., Wohl, D. A., Achhra, A. C., Tambussi, G., O’Connor, J. L., Stein, J. H., Duprez, D., Neaton, J., et al. (2015) · HIV Medicine · doi:10.1111/hiv.12233 · Cited by 32
Self-citation
Impact of switch from tenofovir disoproxil fumarate-based regimens to tenofovir alafenamide-based regimens on lipid profile, weight gain and cardiovascular risk score in people living with HIV
Plum, P., Maes, N., Sauvage, A.-S., Frippiat, F., Meuris, C., Uurlings, F., Lecomte, M., Léonard, P., Paquot, N., Fombellida, K., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06479-9 · Cited by 32
Obesity in young South African women living with HIV: A cross-sectional analysis of risk factors for cardiovascular disease
Hanley, S., Moodley, D., & Naidoo, M. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255652 · Cited by 32
Human immunodeficiency virus and menopause
Kanapathipillai, R., Hickey, M., & Giles, M. (2013) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e318282aa57 · Cited by 32
Effect of Darunavir on Lipid Profile in HIV-Infected Patients
Overton, E. T., Arathoon, E., Baraldi, E., & Tomaka, F. L. (2012) · HIV Clinical Trials · doi:10.1310/hct1305-256 · Cited by 32
Epidemiology and Management of Antiretroviral-Associated Cardiovascular Disease
Chastain, D. B., Henderson, H. M., & Stover, K. R. (2015) · The Open AIDS Journal · doi:10.2174/1874613601509010023 · Cited by 32
Statins to improve cardiovascular outcomes in treated HIV infection
Longenecker, C. T., Eckard, A. R., & McComsey, G. A. (2015) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000223 · Cited by 31
Short Communication: Do Cytomegalovirus Antibody Levels Associate with Age-Related Syndromes in HIV Patients Stable on Antiretroviral Therapy?
Brunt, S. J., Cysique, L. A., Lee, S., Burrows, S., Brew, B. J., & Price, P. (2016) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2015.0328 · Cited by 31
Cardiac Disease Associated with Human Immunodeficiency Virus Infection
Bloomfield, G. S., & Leung, C. L. (2016) · Cardiology Clinics · doi:10.1016/j.ccl.2016.09.003 · Cited by 31
The cardiovascular risk management for people living with HIV in Europe
Shahmanesh, M., Schultze, A., Burns, F. M., Kirk, O., Lundgren, J. D., Mussini, C., Pedersen, C., Wit, S. D., Kutsyna, G. A., & Mocroft, A. (2016) · AIDS · doi:10.1097/qad.0000000000001207 · Cited by 30
Self-citation
Cardiovascular risk in advanced naïve HIV-infected patients starting antiretroviral therapy: Comparison of three different regimens - PREVALEAT II cohort
Maggi, P., Bellacosa, C., Leone, A., Volpe, A. R., Ricci, E. D., Ladisa, N., Cicalini, S., Grilli, E., Viglietti, R., Chirianni, A., et al. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.05.004 · Cited by 30
The prevalence of selected non-communicable disease risk factors among HIV patients on anti-retroviral therapy in Bushbuckridge sub-district, Mpumalanga province
Mathebula, R. L., Maimela, E., & Ntuli, N. S. (2020) · BMC Public Health · doi:10.1186/s12889-019-8134-x · Cited by 31
Plasma plasminogen activator inhibitor-1 predicts myocardial infarction in HIV-1-infected individuals
Knudsen, A., Katzenstein, T. L., Benfield, T., Jørgensen, N. R., Kronborg, G., Gerstoft, J., Obel, N., Kjær, A., & Lebech, A. (2014) · AIDS · doi:10.1097/qad.0000000000000247 · Cited by 30
Neutrophil to Lymphocyte Ratio and Cardiovascular Disease Incidence in HIV-Infected Patients: A Population-Based Cohort Study
Quirós-Roldán, E., Raffetti, E., Donato, F., Magoni, M., Pezzoli, C., Ferraresi, A., Brianese, N., Castelnuovo, F., Focà, E., & Castelli, F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0154900 · Cited by 30
Metabolic disorders and cardiovascular risk in people living with HIV/AIDS without the use of antiretroviral therapy
Raposo, M. A., Armiliato, G. N. D. A., Guimarães, N. S., Caram‐Deelder, C., Silveira, R. D. D. S., & Tupinambás, U. (2017) · Revista da Sociedade Brasileira de Medicina Tropical · doi:10.1590/0037-8682-0258-2017 · Cited by 29
Physical Activity Affects Brain Integrity in HIV+ Individuals
Ortega, M., Baker, L. M., Vaida, F., Paul, R. H., Basco, B., & Ances, B. M. (2015) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617715000879 · Cited by 28
The Use of Primary Prevention Statin Therapy in Those Predisposed to Atherosclerosis
Garshick, M. S., & Underberg, J. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0685-7 · Cited by 28
Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis
Okeke, N. L., Chin, T., Clement, M. E., Chow, S., & Hicks, C. B. (2015) · AIDS Care · doi:10.1080/09540121.2015.1099602 · Cited by 28
Metabolites predict cardiovascular disease events in persons living with HIV: a pilot case–control study
Okeke, N. L., Craig, D. M., Muehlbauer, M. J., Ilkayeva, O., Clement, M. E., Naggie, S., & Shah, S. H. (2018) · Metabolomics · doi:10.1007/s11306-018-1318-z · Cited by 27
HIV infection, aging and cardiovascular disease: epidemiology and prevention
Petoumenos, K., & Worm, S. W. (2011) · Sexual Health · doi:10.1071/sh11020 · Cited by 30
Self-citation
Cardiovascular disease risk scores’ relationship to subclinical cardiovascular disease among HIV-infected and HIV-uninfected men
Monroe, A. K., Haberlen, S., Post, W. S., Palella, F. J., Kinsgley, L. A., Witt, M. D., Budoff, M. J., Jacobson, L. P., & Brown, T. T. (2016) · AIDS · doi:10.1097/qad.0000000000001163 · Cited by 27
Longitudinal Analysis of the Associations between Antiretroviral Therapy, Viraemia and Immunosuppression with Lipid Levels: The D:A:D Study
Kamara, D. A., Smith, C. J., Ryom, L., Reiss, P., Rickenbach, M., Phillips, A. N., Mocroft, A., Wit, S. D., Law, M. G., Monforte, A. D., et al. (2015) · Antiviral Therapy · doi:10.3851/imp3051 · Cited by 26
Self-citation
Coronary artery disease and HIV; getting to the HAART of the matter
Mavroudis, C. A., Majumder, B., Loizides, S., Christophides, T., Johnson, M. A., & Rakhit, R. D. (2012) · International Journal of Cardiology · doi:10.1016/j.ijcard.2012.09.043 · Cited by 26
Prevalence and associated risk factors of peripheral artery disease in virologically suppressed HIV-infected individuals on antiretroviral therapy in Kwara state, Nigeria: a cross sectional study
Agu, C. E., Uchendu, I. K., Nsonwu-Anyanwu, A. C., Okwuosa, C. N., & Achukwu, P. U. (2019) · BMC Public Health · doi:10.1186/s12889-019-7496-4 · Cited by 26
Cardiovascular risk in HIV-infected individuals: A comparison of three risk prediction algorithms
Policarpo, S., Rodrigues, T., Moreira, A. C., & Valadas, E. (2019) · Revista Portuguesa de Cardiologia · doi:10.1016/j.repc.2019.08.002 · Cited by 25
The dawn of precision medicine in HIV: state of the art of pharmacotherapy
Mu, Y., Kodidela, S., Wang, Y., Kumar, S., & Cory, T. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1515916 · Cited by 23
Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use
Maggi, P., Socio, G. V. D., Cicalini, S., D’Abbraccio, M., d’Ettorre, G., Biagio, A. D., Martinelli, C. V., Nunnari, G., Rusconi, S., Sighinolfi, L., et al. (2019) · AIDS Research and Therapy · doi:10.1186/s12981-019-0226-2 · Cited by 23
Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy
Begovać, J., Dragović, G., Višković, K., Kušić, J., Mihanović, M. P., Lukas, D., & Jevtović, D. (2015) · Croatian Medical Journal · doi:10.3325/cmj.2015.56.14 · Cited by 23
Lopinavir/Ritonavir Versus Darunavir Plus Ritonavir for HIV Infection: A Cost-Effectiveness Analysis for the United States
Simpson, K. N., Pei, P. P., Möller, J., Baran, R. W., Dietz, B., Woodward, W. C., Migliaccio–Walle, K., & Jaime, J. (2013) · PharmacoEconomics · doi:10.1007/s40273-013-0048-3 · Cited by 23
Lipid profile of HIV-infected patients in relation to antiretroviral therapy: a review
Souza, S. J., Luzia, L. A., dos Santos, S. D. S., & Rondó, P. H. D. C. (2013) · Revista da Associação Médica Brasileira (English Edition) · doi:10.1016/s2255-4823(13)70454-5 · Cited by 23
Comparison of the ACC/AHA and Framingham algorithms to assess cardiovascular risk in HIV-infected patients
Neto, L. F. D. S. P., Dias, F. R., Bressan, F. F., & Santos, C. R. O. (2017) · The Brazilian Journal of Infectious Diseases · doi:10.1016/j.bjid.2017.06.007 · Cited by 22
Dyslipidemias and Elevated Cardiovascular Risk on Lopinavir-Based Antiretroviral Therapy in Cambodia
Limsreng, S., Marcy, O., Ly, S., Ouk, V., Hak, C., Thavary, S., Ban, B., Canestri, A., Viretto, G., Delfraissy, J., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0160306 · Cited by 22
Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment–Experienced People Living With Human Immunodeficiency Virus
Greenberg, L., Ryom, L., Neesgaard, B., Wandeler, G., Staub, T., Gisinger, M., Skoll, M., Günthard, H. F., Scherrer, A., Mussini, C., et al. (2020) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1878 · Cited by 21
Self-citation
Cardiovascular risk factors and lifetime risk estimation in HIV-infected patients under antiretroviral treatment in Spain
Estrada, V., Bernardino, J. I., Masiá, M., Iribarren, J. A., Ortega, A., Lozano, F., Miralles, C., Olalla, J., Santos, J., Pérez-Elı́as, M. J., et al. (2015) · HIV Clinical Trials · doi:10.1179/1528433614z.0000000008 · Cited by 21
Atherosclerotic Cardiovascular Disease and Anti-Retroviral Therapy
Kaplan‐Lewis, E., Aberg, J. A., & Lee, M.-K. (2016) · Current HIV/AIDS Reports · doi:10.1007/s11904-016-0331-y · Cited by 21
Coronary Artery Disease in Patients with HIV Infection: An Update
Patel, A., & Budoff, M. J. (2020) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-020-00451-9 · Cited by 21
The dynamic risk factors of cardiovascular disease among people living with HIV: a real-world data study
Liu, Z., Zhang, J., Yang, X., Gao, H., Chen, S., Weissman, S., Olatosi, B., & Li, X. (2024) · BMC Public Health · doi:10.1186/s12889-024-18672-x · Cited by 20
Circulating CD4+ TEMRA and CD4+ CD28− T cells and incident diabetes among persons with and without HIV
Bailin, S. S., Kundu, S., Wellons, M., Freiberg, M. S., Doyle, M. F., Tracy, R. P., Justice, A. C., Wanjalla, C. N., LANDAY, A. L., So‐Armah, K., et al. (2021) · AIDS · doi:10.1097/qad.0000000000003137 · Cited by 20
Factors affecting affect cardiovascular health in Indonesian HIV patients beginning ART
Karim, B., Wijaya, I. P., Rahmaniyah, R., Ariyanto, I. A., Waters, S., Estiasari, R., & Price, P. (2017) · AIDS Research and Therapy · doi:10.1186/s12981-017-0180-9 · Cited by 20
Subclinical atherosclerosis in low Framingham risk HIV patients
León, R., Reus, S., López, N., Portilla, I., Sánchez–Payá, J., Giner, L., Boix, V., Merino, E., Torrús, D., Moreno, Ó., et al. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12780 · Cited by 19
Mortal allies
Mayne, E. S., & George, J. A. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000342 · Cited by 19
Mind the gap: difference between Framingham heart age and real age increases with age in HIV-positive individuals–a clinical cohort study
Davies, T.-L., Gompels, M. M., Johnston, S. L., Bovill, B. A., & May, M. (2013) · BMJ Open · doi:10.1136/bmjopen-2013-003245 · Cited by 19
Metabolic Disorders and Cardiovascular Risk in Treatment-Naive HIV-Infected Patients of Sub-Saharan Origin Starting Antiretrovirals: Impact of Westernized Lifestyle
Eholié, S. P., Lacombe, K., Krain, A., Diallo, Z., Ouiminga, M., Campa, P., Bouchaud, O., Bissagnené, E., & Girard, P. (2015) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2014.0164 · Cited by 18
Transgenic mouse model with deficient mitochondrial polymerase exhibits reduced state IV respiration and enhanced cardiac fibrosis
Koczor, C. A., Torres, R. A., Fields, E. J., Qin, Q., Park, J., Ludaway, T., Russ, R. B., & Lewis, W. (2012) · Laboratory Investigation · doi:10.1038/labinvest.2012.146 · Cited by 19
Cardiovascular Complications of HIV-Associated Immune Dysfunction
Zaaqoq, A. M., Khasawneh, F. A., & Smalligan, R. D. (2015) · Cardiology Research and Practice · doi:10.1155/2015/302638 · Cited by 21
Effects of Therapy with Maraviroc on the Carotid Intima Media Thickness in HIV-1/HCV Co-infected Patients
Maggi, P., Bruno, G., Perilli, F., Saracino, A., Volpe, A. R., Santoro, C. R., Ladisa, N., & Angarano, G. (2017) · In Vivo · doi:10.21873/invivo.11035 · Cited by 17
Prediction models for cardiovascular disease risk among people living with HIV: A systematic review and meta-analysis
Yu, J., Liu, X., Zhu, Z., Yang, Z., He, J., Zhang, L., & Lu, H. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1138234 · Cited by 16
Heart failure in patients with human immunodeficiency virus
Cannillo, M., D’Ascenzo, F., Marra, W. G., Cerrato, E., Calcagno, A., Omedè, P., Bonora, S., Mancone, M., Vizza, C. D., DiNicolantonio, J. J., et al. (2014) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000168 · Cited by 16
Resveratrol Co-Treatment Attenuates the Effects of HIV Protease Inhibitors on Rat Body Weight and Enhances Cardiac Mitochondrial Respiration
Symington, B., Mapanga, R. F., Norton, G. R., & Essop, M. F. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170344 · Cited by 16
Assessment of the agreement between the Framingham and DAD risk equations for estimating cardiovascular risk in adult Africans living with HIV infection: a cross-sectional study
Noumegni, S. R., Moor, V. J. A., Assah, F. K., Bigna, J. J., Nansseu, J. R., Kameni, J. A. M., Katte, J.-C. N., Dehayem, M. Y., Kengne, A. P., & Sobngwi, E. (2017) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-017-0055-z · Cited by 16
Predictive factors and prevalence of microalbuminuria in HIV-infected patients: a cross-sectional analysis
Falasca, K., Nicola, M. D., Porfilio, I., Ucciferri, C., Schiaroli, E., Gabrielli, C., Francisci, D., & Vecchiet, J. (2017) · BMC Nephrology · doi:10.1186/s12882-017-0672-9 · Cited by 16
Cardiovascular markers of inflammation and serum lipid levels in HIV-infected patients with undetectable viremia
Višković, K., Lepej, S. Ž., Gorenec, A., Grgić, I., Lukas, D., Zekan, Š., Dragobratović, A., Trupković, M., & Begovać, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-24446-4 · Cited by 16
Cardiovascular risk evaluation of HIV‐positive patients in a case‐control study: comparison of the D:A:D and Framingham equations
Markowicz, S., Delforge, M., Necsoi, C., & Wit, S. D. (2014) · Journal of the International AIDS Society · doi:10.7448/ias.17.4.19515 · Cited by 15
Prevention of stroke in people living with HIV
Nguyen, I., Kim, A. S., & Chow, F. C. (2020) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2020.01.006 · Cited by 17
18Fluoride-based molecular imaging of coronary atherosclerosis in HIV infected patients
Guaraldi, G., Milić, J., Prandini, N., Ligabue, G., Esposito, F., Ciusa, G., Malagoli, A., Scaglioni, R., Besutti, G., Beghetto, B., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.02.014 · Cited by 15
Cardiovascular disease in human immunodeficiency virus
Cheruvu, S., & Holloway, C. J. (2014) · Internal Medicine Journal · doi:10.1111/imj.12381 · Cited by 14
Screening and management of cardiovascular disease in Australian adults with HIV infection
Chan, D. J., Gracey, D. M., Bailey, M., Richards, D., & Dalton, B. S. (2013) · Sexual Health · doi:10.1071/sh13009 · Cited by 14
Diagnosis and Management of Dyslipidemia
Myerson, M. L. (2019) · Springer eBooks · doi:10.1007/978-3-030-10451-1_3 · Cited by 14
Prediction of future cardiovascular events by Framingham, SCORE and asCVD risk scores is less accurate in HIV‐positive individuals from the HIV‐HEART Study compared with the general population
Schulz, C., Mavarani, L., Reinsch, N., Albayrak-Rena, S., Potthoff, A. V., Brockmeyer, N. H., Hower, M., Erbel, R., Jöckel, K., Schmidt, B., et al. (2021) · HIV Medicine · doi:10.1111/hiv.13124 · Cited by 14
Weight Gain and Lipid Profile Changes in Koreans with Human Immunodeficiency Virus undergoing Integrase Strand Transfer Inhibitor-Based Regimens
Kim, J., Nam, H.-J., Jung, Y.-J., Lee, H.-J., Kim, S. E., Kang, S., Park, K. H., Chang, H., Kim, S., Chung, E., et al. (2022) · Infection and Chemotherapy · doi:10.3947/ic.2022.0063 · Cited by 14
Associations between lipids and subclinical coronary atherosclerosis
Whelton, S. P., Deal, J. A., Zikusoka, M. N., Jacobson, L. P., Sarkar, S., Palella, F. J., Kingsley, L., Budoff, M. J., Witt, M. D., Brown, T. T., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002151 · Cited by 14
Lipid Disorders in People with HIV
Sarkar, S., & Brown, T. T. (2021) · Europe PMC (PubMed Central) · Cited by 13
Higher Risk of Dyslipidemia With Coformulated Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide than Efavirenz, Lamivudine, and Tenofovir Disoproxil Fumarate Among Antiretroviral-Naive People Living With HIV in China
Sun, L., He, Y., Xu, L., Zhao, F., Zhou, Y., Zhang, L., Peng, Q., Zhang, H., Zhang, Q., Cao, T., et al. (2022) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000003040 · Cited by 13
Direct and indirect cardiovascular and cardiometabolic sequelae of the combined anti-retroviral therapy on people living with HIV
Batta, Y., King, C., Cooper, F., Johnson, J. L., Haddad, N., Boueri, M. G., DeBerry, E., & Haddad, G. E. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1118653 · Cited by 17
Association of Residual Plasma Viremia and Intima-Media Thickness in Antiretroviral-Treated Patients with Controlled Human Immunodeficiency Virus Infection
Boyd, A. C., Meynard, J., Morand‐Joubert, L., Michon, A., Boccara, F., Bastard, J., Samri, A., Haddour, N., Mallat, Z., Capeau, J., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0113876 · Cited by 13
C-Reactive Protein as an Independent Cardiovascular Risk Predictor in HIV+ Patients: A Focused Review of Published Studies
Gilotra, T. S., & Geraci, S. A. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3154w · Cited by 13
Cardiovascular disease and diabetes in HIV ‐positive and HIV‐negative gay and bisexual men over the age of 55 years in Australia: insights from the Australian Positive & Peers Longevity Evaluation Study
Puhr, R., Petoumenos, K., Huang, R., Templeton, D. J., Woolley, I. J., Bloch, M., Russell, D. B., Law, M. G., & Cooper, D. (2018) · HIV Medicine · doi:10.1111/hiv.12689 · Cited by 15
Self-citation
Uptake and effectiveness of two-drug compared with three-drug antiretroviral regimens among HIV-positive individuals in Europe
Neesgaard, B., Pelchen–Matthews, A., Ryom, L., Florence, É., Peters, L., Roen, A. O., Svedhem, V., Clarke, A. E., Benfield, T., Мицура, В. М., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002320 · Cited by 13
Self-citation
Gut microbiota from Mexican patients with metabolic syndrome and HIV infection: An inflammatory profile
Amador-Lara, F., Andrade-Villanueva, J. F., Vega‐Magaña, N., Rodríguez, M. P., Álvarez-Zavala, M., Sánchez-Reyes, K., Toscano-Piña, M., Peregrina-Lucano, A. A., del Toro‐Arreola, S., González-Hernández, L. A., et al. (2022) · Journal of Applied Microbiology · doi:10.1111/jam.15505 · Cited by 13
The value of flow cytometry in the measurement of platelet activation and aggregation in human immunodeficiency virus infection
Nkambule, B. B., Davison, G. M., & Ipp, H. (2014) · Platelets · doi:10.3109/09537104.2014.909021 · Cited by 13
High correlation between Framingham equations with BMI and with lipids to estimate cardiovascular risks score at baseline in HIV-infected adults in the Temprano trial, ANRS 12136 in Côte d’Ivoire
Guéhi, C., Gabillard, D., Moh, R., Badjé, A., Kouamé, G. M., Oouttara, E., AHIBO, H. F. T., N’Takpé, J. B., Lecarrou, J., Eholié, S. P., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0177440 · Cited by 13
Excess heart age in adult outpatients in routine HIV care
Thompson‐Paul, A. M., Palella, F. J., Rayeed, N., Ritchey, M. D., Lichtenstein, K. A., Patel, D., Yang, Q., Gillespie, C., Loustalot, F. V., Patel, P., et al. (2019) · AIDS · doi:10.1097/qad.0000000000002304 · Cited by 13
Pathophysiology and Clinical Management of Dyslipidemia in People Living with HIV: Sailing through Rough Seas
Papantoniou, E., Arvanitakis, K., Markakis, K., Papadakos, S. P., Tsachouridou, Ο., Popovic, D. S., Koufakis, T., Germanidis, G. S., & Kotsa, K. (2024) · Life · doi:10.3390/life14040449 · Cited by 14
Are we successfully managing cardiovascular disease in people living with HIV?
Hatleberg, C. I., Lundgren, J. D., & Ryom, L. (2017) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000417 · Cited by 12
Self-citation
Menthol Cigarettes and the Cardiovascular Risks of People Living With HIV
Míguez‐Burbano, M. J., Vargas, M., Quiros, C., Lewis, J. E., Espinoza, L. A., & Asthana, D. (2014) · Journal of the Association of Nurses in AIDS Care · doi:10.1016/j.jana.2014.01.006 · Cited by 12
Heart failure in HIV infection
Ng, B., MacPherson, P., Haddad, T., & Dwivedi, G. (2014) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000041 · Cited by 12
Lipid Management in Human Immunodeficiency Virus
Myerson, M. L. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.010 · Cited by 12
Smoking and projected cardiovascular risk in an HIV ‐positive Asian regional cohort
Do, T., Boettiger, D. C., Law, M. G., Pujari, S. N., Zhang, F., Chaiwarith, R., Kiertiburanakul, S., Lee, M., Ditangco, R. A., Wong, W. W., et al. (2016) · HIV Medicine · doi:10.1111/hiv.12358 · Cited by 11
Self-citation
Screening and risk assessment for coronary artery disease in HIV infection: an unmet need
Nadel, J., & Holloway, C. (2016) · HIV Medicine · doi:10.1111/hiv.12422 · Cited by 11
The data‐collection on adverse effects of anti‐HIV drugs (D:A:D) model for predicting cardiovascular events: External validation in a diverse cohort of people living with HIV
Anikpo, I. O., Agovi, A. M., Cvitanovich, M. J., Lonergan, F. R., Johnson, M. E., & Ojha, R. P. (2021) · HIV Medicine · doi:10.1111/hiv.13147 · Cited by 10
Risk of Coronary Heart Disease among HIV‐Infected Patients: A Multicenter Study in Brazil
Fuchs, S. C. P. C., de Alencastro, P. R., Ikeda, M. L. R., Barcellos, N. T., Wolff, F. H., Brandão, A. B. D. M., Ximenes, R. A. A., Miranda-Filho, D. D. B., Lacerda, H. R., de Albuquerque, M. D. F. P. M., et al. (2013) · The Scientific World JOURNAL · doi:10.1155/2013/163418 · Cited by 11
Care of the aging HIV patient
Blaylock, J. M., & Wortmann, G. W. (2015) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.82a.14094 · Cited by 11

Authors: Friis-Møller, N., Thiébaut, R., Reiss, P., Weber, R., D'Arminio Monforte, A., De Wit, S., El-Sadr, W., Fontas, E., Worm, S., Kirk, O., Phillips, A., Sabin, C. A., Lundgren, J. D., Law, M. G., & DAD study group
Affiliations: Copenhagen HIV Programme (CHIP), University of Copenhagen/Faculty of Health Science, Copenhagen, Denmark
Inserm (FR)
Amsterdam UMC Location University of Amsterdam (NL)
University Hospital Zurich (CH)
ICONA, Hospital San Paolo, University of Milan, Italy
Saint-Pierre Cohort, CHU Saint-Pierre Hospital, Brussels, Belgium
Columbia University Irving Medical Center (US)
Nice Cohort, CHU Nice Hopital de l'Archet, Nice, France
University of Copenhagen (DK)
The Royal Free Hospital (GB)
AHOD, National Centre in HIV Epidemiology and Clinical Research, Sydney, Australia
ORCID: Thiébaut, Rodolphe
Reiss, Peter
Weber, Rainer
El-Sadr, Wafaa
Kirk, Ole
Phillips, Andrew
Sabin, Caroline A.
Lundgren, Jens D.
Law, Matthew G.
Venue: European Journal of Cardiovascular Prevention & Rehabilitation
Publisher: Oxford University Press (OUP)
Published: 2010-10
Volume: 17
Issue: 5
Pages: 491-501
ISSN: 1741-8267 (ISSN-L)
DOI: 10.1097/hjr.0b013e328336a150
OpenAlex: W2160970334
Cited by: 384
References: 43
Citations by year: 2026: 6 · 2025: 11 · 2024: 13 · 2023: 12 · 2022: 16 · 2021: 28 · 2020: 23 · 2019: 25 · 2018: 16 · 2017: 38 · 2016: 36 · 2015: 43 · 2014: 24 · 2013: 33 · 2012: 34
FWCI: 28.09
Type: journal article
Language: en
Open access: green
doi.org
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: European Journal of Cardiovascular Prevention & Rehabilitation (publishedVersion)
PubMed (publishedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion)
Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
Murdoch University Research Portal (submittedVersion)
Data Archiving and Networked Services (DANS) (submittedVersion)
Leiden Repository (Leiden University) (submittedVersion)
Ghent University Academic Bibliography (Ghent University) (submittedVersion)
Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Figshare (submittedVersion)
Research Portal (King's College London) (submittedVersion)
Pure Amsterdam UMC (submittedVersion)
Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
Radboud Repository (Radboud University) (submittedVersion)
Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
Zurich Open Repository and Archive (University of Zurich)
Funders: National Science Foundation
Bristol-Myers Squibb
Pfizer
GlaxoSmithKline
Gilead Sciences
European Commission (BIOMED2, CT94-1637, CT97-2713, QLK2-2000-00773)
Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
National Institutes of Health
National Institute of Allergy and Infectious Diseases (U01AI046362, U01AI042170, U01AI069907)
Cilag
Topics: Health Sciences › Medicine › Infectious Diseases › HIV-related health complications and treatments
Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Infectious Diseases › HIV/AIDS Research and Interventions
Keywords: cardiovascular risk prediction, HIV infection, antiretroviral therapy, highly active antiretroviral therapy, metabolic complications, myocardial infarction, coronary artery disease, indinavir, lopinavir/ritonavir, abacavir, Framingham risk score, cardiovascular risk factors
MeSH terms: Adult, Argentina, Australia, Coronary Disease, Drug Therapy, Combination, Europe, Female, Humans, Male, Middle Aged, Myocardial Infarction, Prospective Studies, Risk Factors, Time Factors, Reproducibility of Results, Models, Statistical, HIV Infections, Treatment Outcome, Risk Assessment, Anti-HIV Agents

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Predicting the risk of cardiovascular disease in HIV-infected patients: the Data collection on Adverse Effects of Anti-HIV Drugs Study

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks